Equities

Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Actions
  • Price (EUR)36.26
  • Today's Change0.600 / 1.68%
  • Shares traded0.00
  • 1 Year change-17.59%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,3311,9872,115
Total Receivables, Net982662
Total Inventory282225
Prepaid expenses------
Other current assets, total184168143
Total current assets2,6422,2032,345
Property, plant & equipment, net243256196
Goodwill, net------
Intangibles, net----29
Long term investments------
Note receivable - long term------
Other long term assets1057542
Total assets2,9902,5342,612
LIABILITIES
Accounts payable261812
Accrued expenses224196130
Notes payable/short-term debt000
Current portion long-term debt/capital leases440.320.93
Other current liabilities, total1549798
Total current liabilities448312241
Total long term debt1,2301,1831,228
Total debt1,2741,1831,229
Deferred income tax------
Minority interest------
Other liabilities, total926467371
Total liabilities2,6031,9611,840
SHAREHOLDERS EQUITY
Common stock0.140.140.14
Additional paid-in capital2,2152,0601,964
Retained earnings (accumulated deficit)(1796)(1430)(1160)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(33)(57)(33)
Total equity387573772
Total liabilities & shareholders' equity2,9902,5342,612
Total common shares outstanding144142141
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.